Oromucosal interferon therapy: Pharmacokinetics and pharmacodynamics

Journal of Interferon and Cytokine Research

Volumn 19, Issue 2, 1999, Pages 157-169

  Eid, Pierre ^a   Meritet, Jean François ^a   Maury, Chantal ^a   Lasfar, Ahmed ^a   Weill, Dominique ^a   Tovey, Michael G ^a,b  

^a Laboratory of Viral Oncology   (France)

^b Laboratory of Viral Oncology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; IODINE 125; LY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERFERON ALPHA1-8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ANIMALIA; MURINAE;

EID: 0033023857     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099314306     Document Type: Article

References (25)

1. TOVEY, M.G., and MAURY, C. (1999). Oromucosal Interferon therapy: marked antiviral and antitumor activity. J. Interferon Cytokine Res. 19, 145-155.
2. FINTER, N.B. (1973). Interferons and inlerferon inducers in vivo: I. Antiviral effects in experimental animals. Front. Biol. 2, 295-360.
3. TOVEY, M.G., BEGON-LOURS, J., and GRESSER, I. (1974). A method for the large scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809-815.
4. MEISTER, A., UZE, G., MOGENSEN, K.E., GRESSER, I., TOVEY, M.G., GRÜTTER, M., and MEYER, F. (1986). Biological activities and receptor binding of two human recombinant interferon and their hybrids. J. Gen. Virol. 67, 1633-1644.
5. GRESSER, I., BOURALI, C., THOMAS, M.-T., and FALCOFF, E. (1968). Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus. Proc. Soc. Exp. Biol. Med. 127, 491-196.
6. 125I-labelled human α interferon to human lymphoid cells. Int. J. Cancer 28, 575-582.
7. HUNTER, W.M., and GREENWOOD, F.C. (1962). Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (Lond.) 194, 495-496.
8. ASANUMA, H., INABA, Y., AIZAWA, C., KURATA, T., and TAMURA, S.-I. (1995). Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. J. Immunol. Methods 187, 41-51.
9. TOVEY, M.G., BEGON-LOURS, J., GRESSER, I., and MORRIS, A.G. (1977). Marked enhancement of interferon production in 5-bromodeoxyuridine treated human lymphoblastoid cells. Nature 267, 455-457.
10. 4. Nature (Lond.) 227, 680-685.
11. BOHOSLAWEC, O., TROWN, P.W., and WILLS, R.J. (1986). Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice. J. Interferon Res. 6, 207-213.
12. TARNOWSKI, S.J., ROY, S.K., LIPTAK, R.A., LEE, D.K., and NING, R.Y. (1986). Large-scale purification of recombinant human leukocyte IFNs. Methods Enzymol. 119, 153-165.
13. CANTELL, K., and PYHÄLÄ, L. (1976). Interferon: properties and production. Pharmacokinetics of human leukocyte interferon. J. Infect. Dis. 133, A6-A12.
14. ser. J. Interferon Res. 12, 411-413.
15. FLEISCHMANN, W.R., JR., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.
16. DUMONT, F.J., PALFREE, R.G.E., and COKER, L.Z. (1986). Phenotypic changes induced by interferon in resting T cells: major enhancement of Ly-6 antigen expression. J. Immunol. 137, 201-210.
17. WILLS, R.J., SPIEGEL, H.E., and SOIKE, K.P. (1984). Pharmacokinetics of recombinant alpha A interferon following IV infusion and bolus, IM, and PO administrations to African green monkeys. J. Interferon Res. 4, 399-409.
18. GIBSON, D.M., COTLER, S., SPIEGEL, H.E., and COLBURN, W.A. (1985). Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J. Interferon Res. 5, 403-408.
19. BEILHARZ, M.W., McDONALD, W., WATSON, M.W., HENG, J., McGEACHIE, J., and LAWSON, C.M. (1997). Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res. 17, 625-630.
20. OKANOUE, T., SAKAMOTO, S., ITOH, Y., MINAMI, M., YASUI, K., SAKAMOTO, M., NISHIOJI, K., KATAGISHI, T., NAKAGAWA, Y., TADA, H., SAWA, Y., MIZUNO, M., KAGAWA, K., and KASHIMA, K. (1996). Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 25, 283-291.
21. KOREN, S., and FLEISCHMANN, W.R., JR. (1993). Orally administered interferons suppress bone marrow function. Proc. Soc. Exp. Biol. Med. 204, 155-164.
22. HOOFNAGLE, J.H., and DI BISCEGLIE, A.M. (1997). The treatment of chronic viral hepatitis. Drug Ther. 336, 347.
23. ROMAGNANI, S. (1997). The Th1/Th2 paradigm. Immunol. Today 18, 263-266.
24. GROH, V., STEINLE, A., BAUER, S., and SPIES, T. (1998). Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279, 1737-1740.
25. EINHORN, S., and GRANDER, D. (1996). Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Res. 16, 275-281.